J&J Q1 profit falls 10 pct despite higher sales

Apr 16, 2013 by Linda A. Johnson
In this Monday, July 16, 2012, photo, Johnson & Johnson products are displayed in Orlando, Fla. Johnson & Johnson reports quarterly financial results before the market opens on Tuesday, April 16, 2013. (AP Photo/John Raoux, File)

Johnson & Johnson's first-quarter profit fell by just over 10 percent as increased sales were offset by higher costs for production, marketing and administration.

The maker of Tylenol, prescription drugs and medical devices said Tuesday that it earned $3.5 billion, or $1.22 per share, down 10.6 percent from $3.9 billion, or $1.41 per share, a year earlier.

Excluding litigation and acquisition-related charges totaling $610 million, income would have been $4.1 billion, or $1.44 per share. That beat analysts' forecast by 4 cents per share.

Revenue totaled $17.5 billion, up 8.5 percent from $16.1 billion a year earlier. Analysts expected of $17.46 billion.

U.S. sales were up 11.2 percent as the company, based in New Brunswick, New Jersey, returned more of its recalled nonprescription drugs to store shelves. International sales grew by 6.3 percent.

Sales climbed 10 percent to $7.06 billion in the medical devices and diagnostics business, J&J's biggest unit. That was partly because of new products acquired last year with orthopedics device maker Synthes, J&J's biggest acquisition ever at $19.1 billion.

Prescription drug revenue rose 10.4 percent to $6.77 billion, led by Invega Sustenna for schizophrenia, three drugs for immune disorders and two new medicines likely to become blockbusters. Those are Xarelto for preventing blood clots and strokes, and prostate cancer pill Zytiga.

Sales of consumer health products edged up 2.2 percent to $3.68 billion.

Production costs jumped 13 percent to $5.55 billion, mainly for an inventory charge related to the Synthes acquisition in 2012's second quarter.

In addition, the company continues to make factory upgrades and undergoes increased regulatory inspections after issuing about three dozen product recalls since 2009, mostly for nonprescription medicines. That's kept Tylenol, Motrin and many other J&J staples out of stores until recently. But CEO Alex Gorsky said in a statement that the company is returning a reliable supply of its over-the-counter medicines to stores.

Explore further: Tycoon Branson backs ride-sharing service Sidecar

not rated yet
add to favorites email to friend print save as pdf

Related Stories

J&J Q3 net income drops 7 percent on higher costs

Oct 16, 2012

Johnson & Johnson's third-quarter profit fell 7 percent as increased research and production costs offset higher sales for its medicines and medical devices and new revenue from its biggest acquisition ever.

Merck's 2Q net falls on charges, but sales rise

Jul 27, 2012

Merck & Co.'s second-quarter net income fell 11.4 percent as slightly higher sales were offset by acquisition and restructuring costs. However, the drugmaker beat Wall Street expectations, and Merck shares ...

Oracle fiscal 3Q net income up 78 pct

Mar 24, 2011

(AP) -- Database software maker Oracle Corp. said Thursday its net income rose 78 percent in the fiscal third quarter, helped by a rise in new software license sales and the benefit of three full months of ...

Amgen 4Q profit drops 16 pct. on higher spending

Jan 23, 2013

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Pfizer Q4 net jumps on sale of nutrition business

Jan 29, 2013

Pfizer Inc.'s fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales of Lipitor and other medicines, because of a $4.8 billion gain from selling its nutrition business. ...

Recommended for you

German court lifts ban on Uber car pick-up service

3 hours ago

The controversial but popular car pick-up service Uber claimed a victory in Germany on Tuesday when a court threw out an injunction levelled against its operations in Europe's biggest economy.

Oligarch buys Russia's most popular social media (Update)

5 hours ago

A media company owned by Kremlin-friendly oligarch Alisher Usmanov has splashed out $1.5 billion to gain full control of Russia's most popular social network, VKontakte, bringing an end to a months-long dispute ...

User comments : 0